Literature DB >> 21659856

Drug provocation tests in hypersensitivity drug reactions.

Ticha Rerkpattanapipat1, Anca-Mirela Chiriac, Pascal Demoly.   

Abstract

PURPOSE OF REVIEW: Drug provocation test (DPT) is necessary to diagnose most drug hypersensitivity reactions (HSRs) due to decreased sensitivity of skin testing even when combined with in-vitro tests in immunonologic drug HSR and limited availability of these tests in nonimmunologic reaction. We review the principles and controversial issues of DPT, and recent studies using DPT as a diagnostic tool. RECENT
FINDINGS: DPT is recommended in the diagnosis of HSR to β-lactams, as well as other drug classes [such as acetylsalicylic acid-NSAIDs (ASA-NSAIDs), non-β-lactams antibiotics, heparin, glucocorticoids, and local anesthetic agents]. In view of the decreased sensitivity of skin testing, limited accessibility to new benzylpenicillin polylysine (PPL)/mixture of minor determinant (MDM) test reagents and limited availability of validated sensitive in-vitro tests, individuals who require DPT to β-lactams are increasing. The negative predictive value of allergologic work-up is very high, ranging from 94 to 98% for β-lactams and those reactions after negative tests are mostly nonimmediate and mild. Finally, DPT is recommended to ascertain tolerability of alternative compound when evaluating cross-reactivity among different classes of β-lactams, NSAIDs and glucocorticoids, and possibly iodinated contrast media.
SUMMARY: DPT is often needed when evaluating patients with suspected drug HSR. More studies regarding standardization of the various protocols are needed in order to increase its acceptance and adoption as a standard practice in the diagnostic algorithm for drug HSR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21659856     DOI: 10.1097/ACI.0b013e328348a4e9

Source DB:  PubMed          Journal:  Curr Opin Allergy Clin Immunol        ISSN: 1473-6322


  8 in total

Review 1.  Antimicrobial stewardship's new weapon? A review of antibiotic allergy and pathways to 'de-labeling'.

Authors:  Jason Trubiano; Elizabeth Phillips
Journal:  Curr Opin Infect Dis       Date:  2013-12       Impact factor: 4.915

2.  Drug desensitization in 17-year-old male with Mast Cell Activation Syndrome, pneumonia, and antibiotic hypersensitivities.

Authors:  Patrick Staso; Andrey Leonov
Journal:  AME Case Rep       Date:  2017-11-30

3.  Cross-reactivity among iodinated contrast agents: should we be concerned?

Authors:  Adrian A Schmid; John N Morelli; Martin N Hungerbühler; Ingrid B Boehm
Journal:  Quant Imaging Med Surg       Date:  2021-09

4.  Testing for drug hypersensitivity syndromes.

Authors:  Craig M Rive; Jack Bourke; Elizabeth J Phillips
Journal:  Clin Biochem Rev       Date:  2013-02

Review 5.  Pro and Contra: Provocation Tests in Drug Hypersensitivity.

Authors:  Ozge Soyer; Umit Murat Sahiner; Bulent Enis Sekerel
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

Review 6.  Assessment of immediate and non-immediate hypersensitivity contrast reactions by skin tests and provocation tests: A review.

Authors:  Rakesh D Bansie; A Faiz Karim; Maurits S van Maaren; Maud Aw Hermans; Paul LA van Daele; Roy Gerth van Wijk; Saskia M Rombach
Journal:  Int J Immunopathol Pharmacol       Date:  2021 Jan-Dec       Impact factor: 3.219

7.  Drug provocation tests: up-date and novel approaches.

Authors:  Anca Mirela Chiriac; Pascal Demoly
Journal:  Allergy Asthma Clin Immunol       Date:  2013-04-03       Impact factor: 3.406

Review 8.  Drug hypersensitivity reactions in Asia: regional issues and challenges.

Authors:  Bernard Yu-Hor Thong; Michaela Lucas; Hye-Ryun Kang; Yoon-Seok Chang; Philip Hei Li; Min Moon Tang; James Yun; Jie Shen Fok; Byung-Keun Kim; Mizuho Nagao; Iris Rengganis; Yi-Giien Tsai; Wen-Hung Chung; Masao Yamaguchi; Ticha Rerkpattanapipat; Wasu Kamchaisatian; Ting Fan Leung; Ho Joo Yoon; Luo Zhang; Amir Hamzah Abdul Latiff; Takao Fujisawa; Francis Thien; Mariana C Castells; Pascal Demoly; Jiu-Yao Wang; Ruby Pawankar
Journal:  Asia Pac Allergy       Date:  2020-01-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.